Q1 2026 Consolidated Earnings: Operating Profit Up 46%, Net Profit Turns to Black
-
Revenue KRW 435.5 billion, up 13.5% YoY
-
Operating profit KRW 11.7 billion, up 46.3% YoY and 154.3% QoQ
-
Profit before tax KRW 28.6 billion, turned to black (vs. -KRW 110.1 billion previous quarter)
-
Net profit KRW 20.1 billion, turned to black (vs. -KRW 102.8 billion previous quarter)
-
Controlling interest net profit KRW 20.5 billion, down 31% YoY
KOSPI Filing Information
-
Filing: Consolidated Financial Statements Basis Operating (Provisional) Results (Fair Disclosure)
-
Company: GC Biopharma (006280)
-
Submission: GC Biopharma Corp.
-
Receipt: 05-08-2026
-
Under KRX KOSPI Market Division